Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

PeptiDream tapped by Merck & Co.
July 2015
SHARING OPTIONS:

TOKYO—PeptiDream Inc. has inked a multitarget discovery and optimization collaboration with Merck & Co. Inc., known as MSD outside of the U.S. and Canada, through a subsidiary. Per the collaboration, PeptiDream will apply its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocylic/constrained peptides against multiple targets of interest selected by Merck. Merck has the right to develop and commercialize all therapeutic peptides that result from this agreement, with an option to non-exclusively license the PDPS technology in the future. PeptiDream will receive an upfront payment and research funding, and is eligible to receive milestone payments based on preclinical and clinical development as well as royalties. The PDPS platform “allows us to rapidly build highly diverse constrained peptide libraries, largely tailored to the individual target, leading to the rapid identification of chemically diverse hits, which can then be quickly assessed for the desired biological activity profiles,” said Kiichi Kubota, PeptiDream’s CEO.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.